| Ssz. | Belső szám | Vizsgálatvezető neve | Protokoll szám | Fázis | Szponzor/CRO |
|---|---|---|---|---|---|
| 1. | GYFKK/2019/69 | Dr. Lampé Rudolf | 2693-CL-0302 | III. | Astellas |
| 2. | GYFKK/2019/116 | Dr. Bittner Nóra | MK-7339-005-01 | III. | MSD |
| 3. | GYFKK/2019/124 | Dr. Árkosy Péter | DZB-CS-201 | II. | Basilea Pharmaceutica International |
| 4. | GYFKK/2019/153 | Prof. Dr. Altorjay István | CNTO1959UCO3001 | II/III. | Janssen |
| 5. | GYFKK/2019/150 | Dr. Árkosy Péter | MO39874 | III. | Roche |
| 6. | GYFKK/2019/154 | Prof. Dr. Fülesdi Béla | MK-8616-169 | IV. | MSD |
| 7. | GYFKK/2019/82 | Dr. Bittner Nóra | 208657 | III. | GSK |
| 8. | GYFKK/2019/155 | Dr. Nagy Andrea | C3591024 | II/A. | Pfizer |
| 9. | GYFKK/2019/151 | Prof. Dr. Remenyik Éva | IM011-075 | III/B. | Bristol-Myers |
| 10. | GYFKK/KEK/45 | Dr. Gaál János | I4V-MC-JAJA | IIIB/IV. | Lilly |
| 11. | GYFKK/KEK/46 | Dr. Lajtos Julianna | AKST4290-211 | II. | ALKAHEST |
| 12. | GYFKK/2019/133 | Dr. Árkosy Péter | NuTide121 | III. | NuCana |
| 13. | GYFKK/2019/111 | Dr. Árkosy Péter | 20140346 | III. | Amgen |
| 14. | GYFKK/2019/149 | Prof. Dr. Csanádi Zoltán | 1VIT15043 | III. | American Regent |
| 15. | GYFKK/2019/160 | Dr. Bessenyei Mónika | 1042-PCDH19-3002 | III. | Marinus |
| 16. | GYFKK/2019/159 | Dr. Oláh László | CTQJ230A12301 | III. | Novartis |
| 17. | GYFKK/2019/162 | Dr. Bittner Nóra | EFC15858 | III. | Sanofi-Aventis |
| 18. | GYFKK/2019/119 | Dr. Árkosy Péter | DS8201-A-U303 | III. | Daiichi Sankyo |
| 19. | GYFKK/2020/3 | Prof. Dr. Illés Árpád | B1931030 | IV. | Pfizer |
| 20. | GYFKK/2019/161 | Dr. Nemes Balázs | CCFZ533A2201 | II. | Novartis |
| 21. | GYFKK/2020/9 | Prof. Dr. Altorjay István | Darvadstrocel-3003 | III. | Millenium |
| 22. | GYFKK/2019/110 | Prof. Dr. Altorjay István | APD334-301 | III. | Arena |
| 23. | GYFKK/2019/158 | Dr. Flaskó Tibor | 204989 | III. | GSK |
| 24. | GYFKK/2019/110 | Prof. Dr. Altorjay István | APD334-301 | III. | Arena |
| 25. | GYFKK/2020/17 | Prof. Dr. Kiss Csongor | EFC16293 | III. | Bioverativ |
| 26. | GYFKK/2020/10 | Prof. Dr. Szegedi Andrea | CZPL389A2203E1 | II. | Novartis |
| 27. | GYFKK/2020/6 | Prof. Dr. Szegedi Andrea | M19-850 | III. | AbbVie |
| 28. | GYFKK/2020/13 | Prof. Dr. Csanádi Zoltán | 20603 | II/B. | Bayer |
| 29. | GYFKK/2020/32 | Dr. Szendreyné Dr. Petró Gizella | I8F-MC-GPGN | III. | Lilly |
| 30. | GYFKK/2020/22 | Prof. Dr. Altorjay István | ABX464-104 | II/B. | Abivax |
| 31. | GYFKK/2019/152 | Prof. Dr. Kappelmayer János | B1931030 | IV. | Pfizer |
| 32. | GYFKK/2019/142 | Prof. Dr. Illés Árpád | SRA-MMB-301 | III. | Sierra |
| 33. | GYFKK/2020/12 | Prof. Dr. Altorjay István | M14-430 | III. | AbbVie |
| 34. | GYFKK/2020/35 | Prof. Dr. Altorjay István | M14-234 | IIB/III. | AbbVie |
| 35. | GYFKK/2020/40 | Dr. Árkosy Péter | MK-3475-975 | III. | MSD |
| 36. | GYFKK/2020/67 | Prof. Dr. Páll Dénes | 1404-0002 | II. | Boehringer Ingelheim |
| 37. | GYFKK/2020/20 | Dr. Árkosy Péter | CPDR001X2X01B | II. | Novartis |
| 38. | GYFKK/2020/54 | Prof. Dr. Remenyik Éva | CAIN457M2301E1 | III. | Novartis |
| 39. | GYFKK/2019/144 | Prof. Dr. Illés Árpád | MOM-M281-006 | II/III. | Momenta |
| 40. | GYFKK/2020/26 | Prof. Dr. Szegedi Andrea | CQGE031C2302E1 | III/B. | Novartis |
| 41. | GYFKK/2020/7 | Prof. Dr. Altorjay István | I6T-MC-AMAP | III. | Lilly |
| 42. | GYFKK/2020/14 | Prof. Dr. Altorjay István | M14-433 | III. | AbbVie |
| 43. | GYFKK/2020/36 | Prof. Dr. Altorjay István | M14-533 | III. | AbbVie |
| 44. | GYFKK/2020/37 | Prof. Dr. Altorjay István | M14-675 | III. | AbbVie |
| 45. | GYFKK/2020/24 | Prof. Dr. Méhes Gábor | B1931030 | IV. | Pfizer |
| 46. | GYFKK/2020/59 | Prof. Dr. Páll Dénes | 1245-0204 | III. | Boehringer Ingelheim |
| 47. | GYFKK/2020/2 | Dr. Schlammadinger Ágota | EFC16293 | III. | Bioverativ |
| 48. | GYFKK/2020/16 | Prof. Dr. Illés Árpád | ARGX-113-1801 | III. | BVBA |
| 49. | GYFKK/2020/73 | Prof. Dr. Páll Dénes | EVQ 101/001 | I. | Eveliqure Biotechnologies GmbH. |
| 50. | GYFKK/2020/11 | Prof. Dr. Szegedi Andrea | HS0004 | III. | UCB |
| 51. | GYFKK/2020/43 | Prof. Dr. Szegedi Andrea | H20-249 | 7. BNJ | AbbVie |
| 52. | GYFKK/2020/38 | Dr. Palatka Károly | HP-301 | III. | Phantom |
| 53. | GYFKK/2020/39 | Dr. Palatka Károly | EE-301 | III. | Phantom |
| 54. | GYFKK/2020/15 | Prof. Dr. Illés Árpád | ASTX727-02 | III. | Astex |
| 55. | GYFKK/2020/30 | Dr. Árkosy Péter | CBYL719G12301 | III. | Novartis |
| 56. | GYFKK/2020/29 | Dr. Árkosy Péter | CBYL719H12301 | III. | Novartis |
| 57. | GYFKK/2020/66 | Dr. Vajas Attila | SB15-3001 | III. | Samsung |
| 58. | GYFKK/2020/28 | Dr. Árkosy Péter | MK-6482-005 | III. | MSD |
| 59. | GYFKK/2020/77 | Prof. Dr. Páll Dénes | DE20ESLMED | I. | Meditop Gyógyszeripari Kft. |
| 60. | GYFKK/2020/23 | Prof. Dr. Szűcs Gabriella | I4V-MC-JAIM | III. | Lilly |
| 61. | GYFKK/2020/41 | Prof. Dr. Illés Árpád | ASTX660-01 | II. | Astex |
| 62. | GYFKK/2020/60 | Prof. Dr. Szegedi Andrea | EFC16460 | III. | Sanofi-Aventis |
| 63. | GYFKK/2020/33 | Dr. Árkosy Péter | MK-3475-992 | III. | MSD |
| 64. | GYFKK/2019/157 | Dr. Árkosy Péter | SMS-0472B | II. | WntResearch AB |
| 65. | GYFKK/2020/44 | Prof. Dr. Méhes Gábor | CBYL719C2401 | 7. BNJ | Novartis |
| 66. | GYFKK/2020/1 | Dr. Vajas Attila | 20170542 | III. | Amgen |
| 67. | GYFKK/2020/70 | Dr. Árkosy Péter | CBYL719C2401 | 7. BNJ | Novartis |
Legutóbbi frissítés:
2023. 03. 01. 09:10